Pompe disease (also known as glycogen storage disease type II or acid maltase deficiency) is a rare, genetic, metabolic disorder. Pompe disease is caused by variations in the acid alpha-glucosidase (GAA) gene which encodes the GAA enzyme.1 The GAA enzyme is responsible for breaking down glycogen within a part of the cell called the lysosome. An insufficient level of the GAA enzyme leads to toxic levels of glycogen, leading to cell death that causes tissue and organ damage. Skeletal and cardiac muscles are the tissues predominantly affected by the disease.
Patients with Pompe disease can experience a wide spectrum of symptoms.1 The adult late-onset form (Late Onset Pompe disease or LOPD) is characterized by slowly-progressing weakness of skeletal muscle, leading over time to decreased motor function and respiratory failure.2 The infantile form of the disease is typically more rapidly-progressing and is characterized by an enlarged heart and liver along with general muscle weakness, feeding difficulties, and respiratory distress. If left untreated, many children with infantile-onset Pompe disease will not live past the first year of life.1
The incidence and progression of Pompe disease vary with age of onset, ethnicity and geography.1 Genetic screening is making it possible to detect Pompe disease in newborns.
The only approved treatment for Pompe disease is enzyme replacement therapy, or ERT, which is a chronic treatment typically delivered in intravenous infusions every other week.1 ERT has markedly improved prognosis for patients with Pompe disease,2 but patients may still develop significant symptoms due to limitations of ERT; patients may also present substantial burdens to caregivers and to the healthcare system.1 Limitations to ERT therapy may be due to insufficient amounts of the externally infused GAA reaching the affected muscle cells and due to patients developing immune reactions to the infused GAA over time.1
Not an actual patient
Community Support & Resources
Those who would like to learn more about Pompe disease may find it useful to visit the websites of patient organizations and other groups that provide support for the Rare Disease community. The links below provide access to several but not all of the organizations that serve patients and caregivers in this disease state. Astellas is not affiliated with and does not endorse any of the organizations listed below. The information provided by Astellas is for informational purposes only and is not meant to replace the advice of a healthcare professional.
|Acid Maltase Deficiency Association|
|International Pompe Association (IPA)|
1.Schoser B, Bilder DA, Dimmock D, Gupta D, James ES, Prasad S. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review. BMC Neurol. 2017;17(1):202. Published 2017 Nov 22. doi:10.1186/s12883-017-0983-2
2. Kishnani et al. 2006 Pompe disease diagnosis and management guideline. Version 1. Genet Med. 8(5): 267–288.